PRESS RELEASE : Atriva Therapeutics Announces Changes to Management

DGAP-News: Atriva Therapeutics GmbH / Key word(s): Personnel 
Atriva Therapeutics Announces Changes to Management 
2021-04-13 / 09:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Atriva Therapeutics Announces Changes to Management 
- Olaf Althaus appointed Chief Financial Officer 
- Stephan Stenglein, M.D., recently joined as Chief Medical Officer 
- Proven track record and 20+ years of experience in their respective fields of expertise 
Tübingen (Germany), April 13, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the 
development of host-targeting antiviral therapies, today announced two changes to its management team. Olaf Althaus was 
appointed Chief Financial Officer, effective May 2020, while Stephan Stenglein, M.D., was named Chief Medical Officer, 
effective February 2021. 
"We are very pleased to have gained two outstanding specialists to complete our management team - each appointee has 
vast experience in their respective fields of expertise. Both have worked in the biotech and pharmaceutical industries 
for the past 20 years at least," said Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics. 
The timing is perfect for Atriva as it is aiming to define and expand the management team's specific areas of 
responsibility: "Olaf and Stephan have joined us at an important time as we are currently entering a critical stage in 
the clinical testing of our lead candidate, ATR-002," noted Dr. Lichtenberger. 
"Besides this, we are honing our financial and organizational strategy to ensure the successful development of ATR-002. 
Olaf brings a wealth of financial acumen and leadership experience to Atriva. Stephan brings years of expertise in the 
late-stage clinical development of respiratory drugs. He will play a crucial role in managing our clinical Phase II 
trial which is key to Atriva's valuation and success. We warmly welcome Olaf and Stephan to the team," added Dr. 
Lichtenberger. 
Olaf Althaus is an experienced biotech entrepreneur and manager with a proven track record of more than 20 years in the 
life science industry. He was co-founder, CEO and CFO at CellMed AG for 12 years and Managing Director at AEterna 
Zentaris GmbH. Before entering the pharmaceutical industry, he worked in private equity and investment banking for 
several financial institutes in Frankfurt and London. Olaf holds a degree in industrial engineering, business 
administration and applied mathematics from Karlsruhe University (Diplom Wirtschaftsingenieurwesen). 
Stephan Stenglein, M.D., is a physician trained in clinical and molecular virology with more than 20 years' experience 
in the pharmaceutical industry, including in medical device and vaccine development. Stephan was previously VP & Head 
Late-Stage Development Respiratory at AstraZeneca from March 2018. Prior to that his posts included Global Program 
Clinical Head and Global Program Medical Director, both in the respiratory field, at Novartis AG; VP Clinical Sciences 
at Glenmark Pharmaceuticals and Global Medical Director at Shire Plc. Stephan holds an M.D. from the Faculty of 
Medicine at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU). 
Atriva Therapeutics has recently started a clinical Phase II trial of their lead candidate ATR-002 in the treatment of 
moderate to severe COVID-19 in hospitalized patients. RESPIRE^[1] - led by Prof. Gernot Rohde, M.D., Head of Pneumology 
and Professor for Respiratory Medicine and Allergology at the Goethe University Hospital, Frankfurt am Main, Germany - 
is a randomized, double-blind, placebo-controlled study currently being conducted at national and international study 
centers, including the Berlin-based Charité. ATR-002 is a small molecule developed against respiratory infection caused 
by RNA viruses. 
About ATR-002's mode of action with dual benefit 
Atriva's lead product ATR-002 is being developed specifically to treat diseases such as influenza and COVID-19, caused 
by RNA viruses. ATR-002 is a clinical stage MEK inhibitor drug candidate targeting the intracellular Raf/MEK/ERK 
signaling pathway. This pathway is central for replication of many RNA viruses, including the influenza virus, 
hantavirus or respiratory syncytial virus (RSV) and also SARS-CoV-2, the virus that causes COVID-19. In influenza virus 
infected cells, the interaction of ATR-002 with MEK (MAPK/ERK kinase) prevents the export of the viral genome protein 
complexes (ribonucleoprotein, RNP) from the nucleus to the cytoplasm, thus blocking the formation of functional new 
viral particles. This ultimately reduces the viral load in the body.^[2] In addition, ATR-002 has the potential to 
modulate the pro-inflammatory cytokine response of the body, avoiding an overshooting cytokine response that can be 
caused by such viral infections. MEK inhibition can reduce the gene expression of some of the cytokines involved, such 
as TNF-?, IL-1ß, IP-10, IL-8, MCP-1 and MIP-1a, and thus mitigate the overactive inflammatory response in the lungs of 
patients who are severely ill with influenza or COVID-19.^[3] 
About Atriva Therapeutics GmbH 
Atriva Therapeutics, founded in 2015, is a biopharmaceutical company that is pioneering the development of 
host-targeting antiviral therapies. It was set up by a team of leading scientists in viral research as well as proven 
industry experts. The company aims to develop a therapy platform to treat severe respiratory diseases induced by RNA 
viruses with a high unmet medical need, such as influenza and COVID-19. The Atriva lead product ATR-002 is a 
first-in-class, host-targeting agent that aims to inhibit viral replication in influenza and to favorably modulate the 
body's immune response. ATR-002 is under clinical development and has successfully completed a Phase I trial to 
demonstrate safety and tolerability in healthy subjects. The Company has started a Phase II study to evaluate efficacy 
in hospitalized COVID-19 patients.^[1] A Phase II study in influenza is due to start later in 2021. The Company owns 11 
patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for 
antiviral therapies. The patent life runs through 2041. Atriva Therapeutics is based in Tübingen and Frankfurt, 
Germany. 
Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de 
For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter. 
Contact:                              Media and Investor Relations: 
Atriva Therapeutics GmbH              MC Services AG 
Dr. Rainer Lichtenberger, CEO         Eva Bauer / Raimund Gabriel 
phone: [phone]             phone: [phone] 
mobile: [phone]             [e-mail] 
[e-mail] 

^[1]RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients with COVID-19. ^[2]Pleschka S et al. Nat Cell Biol 2001 Feb 3:301-5; Planz O Antiviral Res 2013 Jun 98(3):457-68; Haasbach E et al. Antiviral Res 2017 Jun 142:178-4; Laure M et al. Antiviral Res 2020 Jun 178:104806. ^[3]Pinto R et al. Antiviral Res 2011 Oct 92(1):45-56; Planz O Antiviral Res 2013 Jun 98(3):457-68; Schräder T et al. Antiviral Res 2018 Sep 157:80-92. -----------------------------------------------------------------------------------------------------------------------

2021-04-13 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

1183773 2021-04-13

(END) Dow Jones Newswires

April 13, 2021 03:30 ET (07:30 GMT)